Comparative Pharmacology
Head-to-head clinical analysis: GASTROCROM versus NEDOCROMIL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GASTROCROM versus NEDOCROMIL SODIUM.
GASTROCROM vs NEDOCROMIL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer; inhibits degranulation of mast cells and release of histamine and other inflammatory mediators.
Nedocromil sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells and other inflammatory cells. It also reduces sensory nerve activation and inhibits eosinophil chemotaxis.
200 mg orally four times daily, 30 minutes before meals and at bedtime.
2 inhalations (2 mg per inhalation) four times daily via metered-dose inhaler, or 2 inhalations (4 mg per inhalation) twice daily via dry powder inhaler.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours following intravenous administration. The apparent half-life after oral inhalation is longer due to slow absorption from the lungs, but systemic half-life remains short, requiring frequent dosing for sustained effect.
Terminal elimination half-life is approximately 2 hours; clinically, this supports twice-daily dosing for sustained effect.
Primarily excreted unchanged in bile and feces via enterohepatic circulation; renal excretion accounts for approximately 1-2% of an oral dose. After intravenous administration, about 50% is excreted unchanged in urine within 48 hours.
Primarily renal excretion of unchanged drug; approximately 70% excreted in urine and 30% in feces via biliary elimination.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer